Latest From Ophthotech Corp.
The New York-headquartered firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.
In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.
Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.
Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health
This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Ophthotech Corp.
- Senior Management
Glenn P Sblendorio, Pres. & CEO
David F Carroll, CFO
Kourous A Rezaei, MD, SVP, CMO
- Contact Info
Phone: (212) 845-8200
One Penn Plaza, Ste. 3520
New York, NY 10119
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.